The ovarian cancer treatment algorithm is rapidly evolving. For decades, chemotherapy has been the standard of care for ovarian cancer; however, treatment is changing to a targeted approach with the introduction of Roche/Genentech/Chugai’s Avastin and three PARP inhibitors: AstraZeneca’s Lynparza, Clovis Oncology’s Rubraca, and Tesaro’s Zejula. Multiple combination therapies using immune checkpoint inhibitors are in late-phase development for ovarian cancer, and we anticipate that this drug class will significantly change the treatment paradigm.
Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.
Primary research: More than 20 country-specific interviews with thought-leading medical oncologists supported by survey data collected for this and other DRG research.
Key companies: Roche/Genentech, Tesaro, Clovis Oncology, AstraZeneca, AbbVie, Merck KGaA, Pfizer, Bristol-Myers Squibb, Merck & Co., ImmunoGen.
Key drugs: Avastin (bevacizumab), Lynparza (olaparib), Zejula (niraparib), Rubraca (rucaparib), Talzenna (talazoparib), Opdivo (nivolumab), Bavencio (avelumab), Tecentriq (atezolizumab), Imfinzi (durvalumab), Keytruda (pembrolizumab), TSR-042, mirvetuximab soravtansine, cediranib, VB-111.
Epidemiology: Diagnosed incident cases of epithelial ovarian cancer by stage at diagnosis (I-IIA, IIB-IIC, III, and IV).
Population segments in market forecast: Early-stage first line, advanced-stage first line, second-line platinum-sensitive, second-line platinum-resistant and -refractory, third-line platinum-sensitive, third-line platinum-resistant and -refractory, and fourth and subsequent lines.
Market forecast features: Ten-year, annualized, drug-level sales and patient share of key ovarian cancer therapies through 2027, segmented by brands/generics and epidemiological subpopulations.